166 related articles for article (PubMed ID: 37057810)
1. Dihydroartemisinin enhances gefitinib cytotoxicity against lung adenocarcinoma cells by inducing ROS-dependent apoptosis and ferroptosis.
Lai XY; Shi YM; Zhou MM
Kaohsiung J Med Sci; 2023 Jul; 39(7):699-709. PubMed ID: 37057810
[TBL] [Abstract][Full Text] [Related]
2. Co-treatment of betulin and gefitinib is effective against EGFR wild-type/KRAS-mutant non-small cell lung cancer by inducing ferroptosis.
Yan WY; Cai J; Wang JN; Gong YS; Ding XB
Neoplasma; 2022 May; 69(3):648-656. PubMed ID: 35330996
[TBL] [Abstract][Full Text] [Related]
3. YES1 as a potential target to overcome drug resistance in EGFR-deregulated non-small cell lung cancer.
Kook E; Lee J; Kim DH
Arch Toxicol; 2024 May; 98(5):1437-1455. PubMed ID: 38443724
[TBL] [Abstract][Full Text] [Related]
4. Curcumin induces EGFR degradation in lung adenocarcinoma and modulates p38 activation in intestine: the versatile adjuvant for gefitinib therapy.
Lee JY; Lee YM; Chang GC; Yu SL; Hsieh WY; Chen JJ; Chen HW; Yang PC
PLoS One; 2011; 6(8):e23756. PubMed ID: 21858220
[TBL] [Abstract][Full Text] [Related]
5. Targeting Adenine Nucleotide Translocase-2 (ANT2) to Overcome Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor in Non-Small Cell Lung Cancer.
Jang JY; Kim YG; Nam SJ; Keam B; Kim TM; Jeon YK; Kim CW
Mol Cancer Ther; 2016 Jun; 15(6):1387-96. PubMed ID: 26883272
[TBL] [Abstract][Full Text] [Related]
6. Gefitinib sensitization of cisplatin-resistant wild-type EGFR non-small cell lung cancer cells.
Li A; Cao W; Liu X; Zhang Y; Ma Y; Xu R; Zhang R; Liu X; Zhou S; Wang R; Liu J; Tang X
J Cancer Res Clin Oncol; 2020 Jul; 146(7):1737-1749. PubMed ID: 32342201
[TBL] [Abstract][Full Text] [Related]
7. Pemetrexed induces ROS generation and cellular senescence by attenuating TS-mediated thymidylate metabolism to reverse gefitinib resistance in NSCLC.
Chen Y; Zhang C; Jin S; Li J; Dai J; Zhang Z; Guo R
J Cell Mol Med; 2023 Jul; 27(14):2032-2044. PubMed ID: 37278440
[TBL] [Abstract][Full Text] [Related]
8. Targeting the epidermal growth factor receptor in non-small cell lung cancer cells: the effect of combining RNA interference with tyrosine kinase inhibitors or cetuximab.
Chen G; Kronenberger P; Teugels E; Umelo IA; De Grève J
BMC Med; 2012 Mar; 10():28. PubMed ID: 22436374
[TBL] [Abstract][Full Text] [Related]
9. Carbonic Anhydrase IX Controls Vulnerability to Ferroptosis in Gefitinib-Resistant Lung Cancer.
Zhang C; Lu X; Liu X; Xu J; Li J; Qu T; Dai J; Guo R
Oxid Med Cell Longev; 2023; 2023():1367938. PubMed ID: 36760347
[TBL] [Abstract][Full Text] [Related]
10. FGL1 regulates acquired resistance to Gefitinib by inhibiting apoptosis in non-small cell lung cancer.
Sun C; Gao W; Liu J; Cheng H; Hao J
Respir Res; 2020 Aug; 21(1):210. PubMed ID: 32778129
[TBL] [Abstract][Full Text] [Related]
11. [Effect of SLC7A11 gene downregulation on the gefitinib resistance of lung adenocarcinoma PC9/GR cells and its mechanism].
Jia YL; Zhao Y; Zhen SM; Cheng ZS; Zheng BY; Liu YP; Liu LH
Zhonghua Zhong Liu Za Zhi; 2023 Sep; 45(9):779-786. PubMed ID: 37805442
[No Abstract] [Full Text] [Related]
12. GLRX inhibition enhances the effects of geftinib in EGFR-TKI-resistant NSCLC cells through FoxM1 signaling pathway.
Wang L; Liu J; Liu J; Chen X; Chang M; Li J; Zhou J; Bai C; Song Y
J Cancer Res Clin Oncol; 2019 Apr; 145(4):861-872. PubMed ID: 30661098
[TBL] [Abstract][Full Text] [Related]
13. Cucurbitacin B Induces the Lysosomal Degradation of EGFR and Suppresses the CIP2A/PP2A/Akt Signaling Axis in Gefitinib-Resistant Non-Small Cell Lung Cancer.
Liu P; Xiang Y; Liu X; Zhang T; Yang R; Chen S; Xu L; Yu Q; Zhao H; Zhang L; Liu Y; Si Y
Molecules; 2019 Feb; 24(3):. PubMed ID: 30759826
[TBL] [Abstract][Full Text] [Related]
14. Delivery of gefitinib in synergism with thymoquinone
Upadhyay P; Ghosh A; Basu A; Pranati PA; Gupta P; Das S; Sarker S; Bhattacharjee M; Bhattacharya S; Ghosh S; Chattopadhyay S; Adhikary A
Biomater Sci; 2021 Dec; 9(24):8285-8312. PubMed ID: 34766965
[TBL] [Abstract][Full Text] [Related]
15. Molecular mechanism of the schedule-dependent synergistic interaction in EGFR-mutant non-small cell lung cancer cell lines treated with paclitaxel and gefitinib.
Cheng H; An SJ; Dong S; Zhang YF; Zhang XC; Chen ZH; Jian-Su ; Wu YL
J Hematol Oncol; 2011 Jan; 4():5. PubMed ID: 21255411
[TBL] [Abstract][Full Text] [Related]
16. [Cigarette Smoke Induces Gefitinib Resistance in NSCLC Cells
via ROS/Sirt3/SOD2 Pathway].
Zi Y; Liao K; Chen H
Zhongguo Fei Ai Za Zhi; 2023 Apr; 26(4):245-256. PubMed ID: 37183639
[TBL] [Abstract][Full Text] [Related]
17. [STE029 Overcomes EGFR-TKI Resistance in Human Lung Adenocarcinoma].
Huang L; Hou M; Liu J; Li Y; Shen W; Zhou Q
Zhongguo Fei Ai Za Zhi; 2022 Nov; 25(11):771-781. PubMed ID: 36419390
[TBL] [Abstract][Full Text] [Related]
18. Cyclosporine A sensitizes human non-small cell lung cancer cells to gefitinib through inhibition of STAT3.
Shou J; You L; Yao J; Xie J; Jing J; Jing Z; Jiang L; Sui X; Pan H; Han W
Cancer Lett; 2016 Aug; 379(1):124-33. PubMed ID: 27264264
[TBL] [Abstract][Full Text] [Related]
19. Xie-Bai-San increases NSCLC cells sensitivity to gefitinib by inhibiting Beclin-1 mediated autophagosome formation.
Ma C; Zhang X; Mo X; Yu Y; Xiao Z; Wu J; Ding L; Lei C; Zhu Y; Zhang H
Phytomedicine; 2024 Mar; 125():155351. PubMed ID: 38232540
[TBL] [Abstract][Full Text] [Related]
20. A novel EGFR inhibitor suppresses survivin expression and tumor growth in human gefitinib-resistant EGFR-wild type and -T790M non-small cell lung cancer.
Wang SP; Hsu YP; Chang CJ; Chan YC; Chen CH; Wang RH; Liu KK; Pan PY; Wu YH; Yang CM; Chen C; Yang JM; Liang MC; Wong KK; Chao JI
Biochem Pharmacol; 2021 Nov; 193():114792. PubMed ID: 34597670
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
